Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,725 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05761977 | Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer(DRIVE) | unknown | — | 50 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 |
| clinicaltrials |
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | unknown | Phase 1 / Phase 2 | 115 | Kartos Therapeutics, Inc.INDUSTRY | 10 | Mar 2, 2023 | clinicaltrials |
| NCT04045834 | Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia | unknown | — | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05466357 | Application Research on Endoscopic Pseudocapsule-Based Resection for Pituitary Adenomas | unknown | N/A | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05693519 | GastroIntestinal Cancer in Children and Adolescents(GICCA) | unknown | — | 2,500 | Paul G. Kemps, MDOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05668767 | Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC | unknown | Phase 2 | 20 | Beijing Chest HospitalOTHER | 0 | Dec 30, 2022 | clinicaltrials |
| NCT05660889 | Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma(AVS for ACC) | unknown | — | 25 | Erasmus Medical CenterOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05595889 | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | unknown | Phase 2 | 40 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 29, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT04996771 | Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05595759 | Violence Against Women in Patients With Alcohol Substance Addiction Training | unknown | N/A | 40 | Abant Izzet Baysal UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT03432299 | Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma(RFAforPTMC) | unknown | N/A | 100 | Seoul National University HospitalOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05034783 | [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05566093 | EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors | unknown | N/A | 20 | Guangxi Medical UniversityOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05554744 | EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors | unknown | N/A | 20 | Guangxi Medical UniversityOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT03478358 | Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | unknown | Phase 1 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05510609 | Three-dimensional Ultrasonography Thyroid Volume Measurement. | unknown | N/A | 17 | Rigshospitalet, DenmarkOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05507593 | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04525638 | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | unknown | Phase 2 | 30 | Fundación de investigación HMOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05483543 | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04756635 | Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity(Performance) | unknown | N/A | 50 | Faculdade de Motricidade HumanaOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05451134 | Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma | unknown | — | 300 | China National Center for Cardiovascular DiseasesOTHER_GOV | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05027100 | Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | unknown | N/A | 33 | Haibo ZhangOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03741517 | Biomarker Study of Pancreatic Neuroendocrine Tumours | unknown | — | 40 | Uppsala UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT04346914 | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT05354700 | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05162196 | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 57 | Wuhan UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT05320458 | Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer | unknown | N/A | 11 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05319704 | Specificities of the Eccentric Exercise: Energy Expenditure and Nature of Oxidized Substrates(Speed-Enso) | unknown | N/A | 12 | University Hospital, Clermont-FerrandOTHER | 1 | Apr 8, 2022 | clinicaltrials |
| NCT02817945 | Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT01441349 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | unknown | Phase 2 | 192 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05299255 | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05268952 | A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0) | unknown | N/A | 100 | University Hospital, AntwerpOTHER | 2 | Mar 7, 2022 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05245994 | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese | unknown | Phase 2 | 60 | Li Zhang, MDOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05247476 | Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients. | unknown | Phase 4 | 50 | Zhongshan Hospital Xiamen UniversityOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04890444 | China Adrenal Disease Registry(CASE) | unknown | — | 2,000 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02446704 | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 66 | Zofia PiotrowskaOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT04295057 | Register of Therapeutical Patients Over 60 Years(ASCLEPIUS) | unknown | — | 12,000 | Eurasian Association of TherapistsOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05191849 | Circulating EV Long RNA Profiles in SCLC | unknown | N/A | 60 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05158491 | Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC | unknown | Phase 1 / Phase 2 | 63 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04901754 | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer(CAMERA) | unknown | Phase 2 | 38 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05113355 | Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm | unknown | Phase 2 | 23 | Peking Union Medical College HospitalOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT05076786 | Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT02041260 | A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | unknown | Phase 2 | 43 | Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 9, 2023source: clinicaltrials